Member Info for Gr33ning68

Ray, you are 100% wrong if you think that rampers or derampers have no affect on the SP. It only takes a difference of a few hundred thousand shares to send the SP up or down 3, 4 or even 5%. So if a deramper or ramper is believable with their so called Facts then it would only take a small amount of investors to buy or sell and make the swing happen. As we know there are many investors on here who hold in excess off 100,000 shares. If they bought in to the idea that someone is plausible enough with their given Facts then they could be swayed. There are a lot on here that aren't researched enough to counter the said posters Facts to make an informed decision. Obviously any said investor should be fully researched before even entering a stock but unfortunately that is not the case. So, to say that rampers or derampers have no affect on Sp imo is wrong. Jmo and not Fact but make your own minds up.
Gla lths. This time next year Rodgers. Lol

Tee'd you up there Larsh....lol

People, DO NOT get into a battle of wits with Ray......... the poor fecker is completely unarmed.

Loatinspace, you should rename yourself lostupmyownarse69. Not good form to counter an argument with my wads bigger than yours. No matter how much money you have it certainly hasn't bought you class. Just saying. All imo of course. Dyor. Not a Doctor

Whilst the initial response date for applications to join is the 07/04/2021, potential providers may join the DPS at any time up to the date the DPS expires so long as the potential provider meets the criteria stated in the procurement documents found on this Contract Finder Notice as well as on Atamis, the appointed e-sourcing platform

To me that says that even if you don't meet that date you can join in later as long as you meet the full requirements. No stress about making 5th 6th or 7th imo

All in your opinion? Well Venture, your opinion is worth **** over here because you are a lying twat for one. Just feck off. You're not invested here, you're just a moronic twat who nobody wants here.

The Shumper is an all year round ensemble. Working in the labs with air con on constantly to keep the machinery and processors cool gives Sir Al the chills.
He's not a physical grafter so doesn't build up any body heat.

I need to take a look at myself if I'm thinking this through so much. Lol

Sorry about the typos peeps. Out walking so difficult typing.

GLA except the mongs. You know who you are

A4uk wtf were you when I'm the SP was going up? Didn't see any comments on how wrong you were on previous posts. Just turn up on red days and stir the shot. Typical TWAT. Feck off you idiot.
Green box for you you melt.

Pmsl. Not bottles he rapping together tho.... its pot noodles

And all those who turn up to roll have to wear sequined spandex monotards. Just saying

Stocktaker, there's absolutely no point coming on here crying about how much our mcap is and how much revenue we have generated. Not one single person on here will give you the answers you want to hear. If you look at our sp and the steady rise then I guess that the whole market disagrees with your opinion. Do yourself a favour and go and take a cold shower and have a word with yourself..... maybe have a word about buying into Avacta yeah. Gl with your decisions but please don't come back to let us know what you decide. No one on here is the slightest bit interest.

Doggy100s pants. Soiled them. Just saying. Lol

Thanks for clearing that up DP. Appreciate it.

Looks to me like we will find out with the trials later this year whether Affimers are the mutts nuts or not.

Am I reading this correctly that doxorubicin trials will be using affimers?

Avacta's tumour microenvironment activated drug conjugates (TMAC) are a ground-breaking new form of cancer immunotherapy, co-invented with Tufts University Medical School, combining Affimers with chemotherapies in a single drug using a linker that is designed to only release the chemotherapy in the tumour microenvironment. This allows extremely potent chemotherapies, too potent to be given to patients systemically, to be combined with Affimer immune-checkpoint therapies.

In order to test the TMAC linker in humans for the first time, a standard-of-care chemotherapy called doxorubicin has been modified with the linker rendering it inactive and harmless until the linker is cleaved in the tumour releasing active doxorubicin. Doxorubicin has well documented safety issues limiting its dosing, and also limiting the patient sub-group that can be treated. Despite these issues, the global doxorubicin market is valued at $910m and is expected to reach $1.4bn by the end of 2025[1]. Avacta's TMAC linker has been shown to increase the maximum tolerated dose of doxorubicin by a factor of six in a pre-clinical study in mice.

So little ever happens? If you're buy in is correct (3p) then you're on a 70 bagger already. Wtf do you want?
There are some very knowledgeable posters on this board who very kindly share their info for free which helps a lot of less informed people. I thank them for their efforts.
You on the other hand have offered what?
Feck off you twat.
Filtered

Hopefully just a 20m order and not a weekly order of 20m. Still doesn't bode well for us. Gutted is an understatement

Looks like that is the case ffs.